Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous TILs in Advanced Glioblastoma Multiforme
NCT05333588Phase 1Unknown
- Sponsor
- Senlang Bio
- Start
- Feb 2022
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes in glioblastoma multiforme (GBM), sponsored by Senlang Bio. Primary endpoint: Number of adverse events related to TiLs infusion at 1 month. Status: unknown.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT05333588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05333588.